Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Featured Open Trials

This important trial funded by DCP is open and actively accruing new participants. More specific information can be found in the links below.

MRI and Gene Expression in Diagnosing Patients with Ductal Breast Cancer In Situ

This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.

NCT02352883 Protocol
Information about the study from ECOG/ACRIN (PDF, 404.5KB)

Preventing High-Risk Adenomas and Second Cancers in Colon Cancer Survivors (S0820)

In this trial, people who have undergone curative surgery for stage 0-3 colon cancer, with or without adjuvant chemotherapy, will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months. Doctors will closely monitor all trial participants throughout the study to detect the recurrence of high-risk adenomas or the development of new colon or rectal cancers.

S0820 Protocol

Featured Clinical Trial Summary

Information for Potential Participants (from SWOG) Exit Disclaimer

Back to Top